TriVisc is indicated for the treatment of pain in osteoarthritis (OA)
of the knee in patients who have failed to respond adequately to
conservative non-pharmacologic therapy and to simple analgesics (e.g. acetaminophen).
TriVisc is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of present infections or skin diseases in the area of the injection site to reduce the potential for developing septic arthritis.
The most commonly reported adverse events in the TriVisc group included injection site pain (6), allergic reaction (3), arthralgia (2), and bleeding at the injection site (2).